Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis

MLA

E. Głodzinska‐Wyszogrodzka, et al. “Cc-Chemokine Eotaxin as a Marker of Efficacy of Specific Immunotherapy in Patients with Intermittent IgE-Mediated Allergic Rhinoconjunctivitis.” Allergy, vol. 58, July 2003, pp. 595–601. EBSCOhost, https://doi.org/10.1034/j.1398-9995.2003.00083.x.

APA

E. Głodzinska‐Wyszogrodzka, Karina Jahnz-Różyk, Tadeusz Płusa, & Tomasz Targowski. (2003). Cc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. Allergy, 58, 595–601. https://doi.org/10.1034/j.1398-9995.2003.00083.x

Chicago

E. Głodzinska‐Wyszogrodzka, Karina Jahnz-Różyk, Tadeusz Płusa, and Tomasz Targowski. 2003. “Cc-Chemokine Eotaxin as a Marker of Efficacy of Specific Immunotherapy in Patients with Intermittent IgE-Mediated Allergic Rhinoconjunctivitis.” Allergy 58 (July): 595–601. doi:10.1034/j.1398-9995.2003.00083.x.